Toward a Bioelectric Systems Theory of Chronic Disease: A Mechanistic and Philosophical Analysis of Insulin Resistance

A Theoretical Investigation at the Intersection of Biophysics, Biochemistry, and Philosophy of Medicine

Nadji Belkheiri[1]

[1]Laboratory for Inorganic, Organic and Bio-Inspired Chemistry Research, Faculty of Exact Sciences and Computer Science, University of Djelfa, PO Box 17000, Djelfa, Algeria
Email: belkheirinadji@yahoo.fr, ORCID: 0000-0002-5499-6216

Abstract

Contemporary biomedicine confronts a persistent epistemic tension: biochemical reductionism has delivered extraordinary explanatory and therapeutic power for acute, linear pathologies, yet remains structurally inadequate for the escalating global burden of complex chronic diseases. We argue that this inadequacy partly reflects a systematic underappreciation of the bioelectrical regulatory architecture that orchestrates molecular processes. Integrating philosophical critiques of reductionism, findings from developmental bioelectricity, and principles of complex systems biology, we advance a neo-bioelectric framework that reconceptualizes the organism as a hierarchically organized, information-processing system in which resting membrane potential (Vmem) gradients constitute an underexplored regulatory layer. This framework is operationalized through a mechanistic analysis of insulin resistance, proposing four chemically specified, testable pathways that may bridge sustained Vmem depolarization to impaired insulin signaling: electrostatic modulation of the insulin receptor, voltage-gated calcium channel-mediated IRS-1 serine phosphorylation, membrane potential-dependent GLUT4 vesicle trafficking, and plasma–mitochondrial membrane potential coupling. We engage alternative models including inflammation-first, mitochondrial dysfunction, and autonomic dysregulation and specify a series of falsifiable predictions with explicit disconfirming outcomes. We further identify the central empirical gap, namely the absence of direct in vivo Vmem mapping in insulin-resistant human tissue, as the core research agenda the framework defines. By recognizing membrane potential gradients as a physical language of physiological control, this framework offers a disciplined expansion of the prevailing paradigm and opens new experimental and conceptual territory for understanding and addressing complex chronic disease.

Keywords: biochemical reductionism, bioelectricity, membrane potential, insulin resistance, voltage-gated calcium channels, IRS-1 phosphorylation, complex chronic disease, philosophy of medicine

1. Introduction: the cognitive dissonance of a successful paradigm

The cognitive dissonance at the heart of contemporary medicine has become intellectually unsustainable. On one axis of evaluation, the biosciences have achieved a precision that borders on the miraculous. The human genome has been sequenced, edited, and functionally annotated to a degree that would have seemed fantastical to the architects of the Human Genome Project. Cryo-electron microscopy now renders the architecture of membrane receptors at near-atomic resolution. High-throughput proteomics and metabolomics generate datasets of staggering complexity, mapping the molecular fluxes that constitute cellular life. The language of molecular biology kinase cascades, G-protein coupled receptor trafficking, epigenetic histone modification has become the unquestioned vernacular of medical education and practice.

On a second, orthogonal axis, the therapeutic yield of this prodigious knowledge remains, in the domain of complex chronic disease, stubbornly meager. The global prevalence of type 2 diabetes mellitus continues its inexorable rise, with the International Diabetes Federation projecting 783 million cases by 2045 (Sun et al., 2022). Autoimmune disorders are increasing in incidence across industrialized nations at rates that resist explanation by genetic drift alone (Lerner et al., 2015). Cardiovascular disease, despite decades of lipid-lowering pharmacotherapy, remains the leading cause of mortality worldwide. The phenomenon of multi-morbidity the co-occurrence of multiple chronic conditions in a single individual has emerged as the defining clinical challenge of the twenty-first century (Whitty & Watt, 2020).

This is not merely a gap between knowledge and application. It is, I submit, evidence of an important structural limitation in the dominant paradigm. Approaches grounded primarily in molecular reductionism appear increasingly insufficient, by themselves, for the systemic, non-linear pathology of chronic disease. The standard response "more molecular detail, more targeted drugs, more personalized genomics" represents an intensification of the same epistemic framework that has produced the current impasse. What is required is not an incremental extension of biochemical reductionism, but a critical examination of its philosophical presuppositions and the construction of a more adequate, multi-level conceptual architecture.

This paper undertakes that examination in three movements. First, it provides a rigorous philosophical critique of biochemical reductionism, distinguishing its legitimate methodological successes from its unwarranted ontological claims. Second, it develops a neo-bioelectric framework integrating findings from developmental biology, electrophysiology, and complex systems theory into a coherent regulatory model. Third, it operationalizes this framework through a detailed case study of insulin resistance, constructing a chemically specified mechanistic bridge and proposing testable hypotheses. Throughout, the argument maintains a disciplined distinction between empirically grounded claims and theoretical extensions.

A brief note on the evidentiary architecture is warranted. The contemporary empirical anchor of this framework is the work of Michael Levin and colleagues on bioelectric control of morphogenesis, regeneration, and cancer suppression (Levin, 2021). Earlier researchers in the bioelectric tradition including Harold Saxton Burr demonstrated the existence of stable organismal electric fields and their correlation with physiological states (Burr, 1972), but these foundational observations are cited here as historical context rather than as primary evidence for the specific mechanistic claims advanced. Where the historical literature is invoked, it serves to establish the pedigree of the bioelectric concept, not to substitute for contemporary experimental validation.

2. The architecture of biochemical reductionism: a philosophical dissection

2.1 Methodological versus ontological reductionism

Any rigorous critique of the dominant medical paradigm must begin with a distinction that is frequently elided in both its defense and its condemnation: the distinction between methodological reductionism and ontological reductionism (Brigandt & Love, 2017; Kaiser, 2015).

Methodological reductionism is the investigative strategy of decomposing complex systems into their constituent parts and studying these parts in isolation. It is a pragmatic heuristic, not a metaphysical claim. Its justification is entirely instrumental: for certain classes of phenomena and certain types of questions, this approach yields reliable, predictive knowledge. The discovery that penicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, that the CFTRΔF508 mutation disrupts chloride channel trafficking in cystic fibrosis, that the BCR-ABL fusion protein drives chronic myeloid leukemia all these represent genuine

triumphs of methodological reductionism. No reasonable critic of the current paradigm denies these achievements, and this paper certainly does not.

Ontological reductionism, by contrast, is the metaphysical assertion that the whole is nothing but the sum of its parts, that all causation in biological systems is exclusively bottom-up, and that the language of molecular interactions is, in principle, sufficient to exhaust the description of living phenomena. It is this ontological claim not the methodological strategy that constitutes an important structural limitation in the context of complex chronic disease.

The conflation of these two forms of reductionism has been remarkably effective as a rhetorical defense of the status quo. The biochemist who successfully elucidates a signaling pathway takes this as confirmation not merely of a useful method, but of a comprehensive ontology. The failure of that ontology to generate effective treatments for chronic disease is then attributed to "incomplete knowledge" rather than to a structural inadequacy of the framework itself. As Kuhn (1962) observed, paradigms are not abandoned at the first sign of anomaly; they are protected by a belt of auxiliary hypotheses that absorb the dissonance between prediction and observation.

2.2 The explanatory asymmetry: acute versus chronic disease

The limitations of a purely reductionist ontology become visible when we examine the differential efficacy of the biochemical paradigm across disease categories. The paradigm excels precisely where the causal chains are linear, short, and molecularly specific. Infectious disease, acute toxicology, single-gene disorders, surgical pathology in these domains, the identification of a molecular culprit and the design of a molecular intervention produces reliable therapeutic outcomes.

Complex chronic diseases type 2 diabetes, metabolic syndrome, autoimmune conditions, neurodegenerative disorders, chronic inflammatory states exhibit a fundamentally different causal architecture. They are characterized by:

1. **Non-linear dynamics:** Small perturbations can produce disproportionate effects; dose-response relationships frequently exhibit non-monotonicity; tipping points and phase transitions are common.
2. **Multi-level causation:** Genetic susceptibility, epigenetic modification, environmental exposures, psychosocial stress, nutritional status, and microbial ecology interact in ways that resist decomposition into independent variables.

3. **Circular causality:** Feedback loops, both positive and negative, operate across temporal and spatial scales, such that the distinction between "cause" and "effect" becomes analytically unstable.
4. **Emergent properties:** System-level behaviors arise that cannot be predicted from, or reduced to, the properties of individual molecular components.

In such systems, a purely molecular intervention a drug targeting a single receptor or enzyme is analogous to attempting to fix a computer's operating system by replacing a single transistor. The intervention may produce measurable effects that register as improvements in surrogate markers, but it does not, and arguably cannot, address the systemic dysregulation that constitutes the disease.

2.3 The surrogate marker problem

This leads to a second-order critique: the biomedical paradigm's structural dependence on surrogate markers as proxies for therapeutic efficacy. The logic is seductive: if elevated HbA1c correlates with diabetic complications, then interventions that lower HbA1c should reduce complications. But this inference is valid only if HbA1c lies on the causal pathway, rather than being a correlate of deeper, unmeasured dysregulation.

The history of medicine is punctuated by therapies that improved surrogate markers while worsening clinical outcomes. The CAST trial demonstrated that antiarrhythmic drugs that successfully suppressed ventricular ectopy (the surrogate) actually increased mortality (the outcome) (Echt et al., 1991). Torcetrapib dramatically raised HDL cholesterol but increased cardiovascular events and mortality (Barter et al., 2007). Rosiglitazone improved glycemic control but increased cardiovascular risk (Nissen & Wolski, 2007). These are not isolated failures. They are symptoms of an epistemological pathology: the systematic confusion of molecular correlates with causal mechanisms, a tendency structurally encoded in a paradigm whose ontology admits no causal forces other than molecular interactions.

2.4 Distinguishing acute and chronic disease paradigms

The conceptual gulf between the acute disease paradigm and the chronic disease paradigm can be rendered schematically to clarify the dimensions along which the dominant model requires expansion. The following table maps this distinction across key dimensions of causal structure, therapeutic logic, and epistemic strategy.

Table 1. Comparative analysis of disease paradigms

Dimension	Acute disease paradigm (Dominant)	Chronic disease paradigm (Required)
Causal structure	Linear chain: A → B → C	Non-linear network with feedback loops
Temporal scale	Hours to days	Months to decades
Therapeutic logic	Interrupt the causal chain at a specific node	Restore system-level regulatory dynamics
Predictive validity	High for molecular endpoints	Requires multi-level, systems-level prediction
Ontological commitment	Bottom-up causation only	Multi-level causation, including constraint-based downward effects
Success metrics	Eradication of pathogen; normalization of acute parameter	Restoration of homeodynamic resilience
Epistemic strategy	Isolate, identify, intervene	Map, model, modulate
Characteristic failure	Resistance to antimicrobials	Surrogate marker improvement without outcome benefit

3. Bioelectricity as an underexplored regulatory layer

3.1 Historical context and contemporary revival

The idea that electrical phenomena play a fundamental role in the organization of living systems is not new. In the late eighteenth century, Luigi Galvani's experiments with frog legs established the existence of "animal electricity," inaugurating a tradition of electrophysiological investigation. Researchers in this tradition most notably Harold Saxton Burr at Yale University demonstrated that all living organisms generate stable, measurable direct current (DC) electric fields that correlate with and predict developmental and physiological events (Burr, 1972). However, the molecular revolution of the mid-twentieth century progressively eclipsed this bioelectric tradition, not through empirical refutation but through a shift in institutional and methodological priorities.

The most significant contemporary revival of this line of inquiry has emerged from the laboratory of Michael Levin at Tufts University. Levin's research program has systematically demonstrated that endogenous bioelectric signals specifically, resting membrane potential (Vmem) gradients constitute a powerful regulatory modality controlling cell behavior, tissue patterning, and whole-organism anatomy (Levin, 2021). While the historical observations of Burr and others established the existence of organismal bioelectric fields, the contemporary empirical foundation for the mechanistic claims advanced in this paper rests primarily on the work of Levin and colleagues, whose experimental manipulations of Vmem have demonstrated causal, not merely correlational, roles for bioelectric signaling in morphogenesis, regeneration, and cancer suppression.

1. **Pattern memory in regeneration:** In planarian flatworms, manipulating Vmem gradients can induce a tail fragment to grow a head, producing a two-headed worm. When these worms are cut again, the two-headed pattern persists even after the experimental manipulation is removed, demonstrating that the bioelectric state has rewritten the anatomical target morphology (Durant et al., 2019).
2. **Oncogenic suppression:** In Xenopus tadpoles injected with human oncogenes, restoring normal Vmem patterns in the surrounding tissue suppresses tumor formation, even in the presence of the oncogene (Chernet & Levin, 2014).
3. **Regenerative induction:** Adult Xenopus limbs, which do not normally regenerate, can be induced to do so by applying a specific, 24-hour bioelectric treatment that re-establishes the Vmem pattern characteristic of embryonic limb development a purely bioelectrical, not genetic, intervention (Tseng & Levin, 2013).
4. **Cellular collective intelligence:** Even non-neural cell collectives including bacteria and cancer cells exhibit primitive forms of learning and memory mediated by bioelectric signaling, as demonstrated by the capacity of bioelectrically trained planarian fragments to retain and transmit adaptive behavioral patterns across regeneration events (Levin, 2021; Durant et al., 2019).

These findings demonstrate that the chemical-genetic apparatus of the cell is not an autonomous executor of a bottom-up program but a subsystem shaped by higher-order bioelectrical signals.

3.2 The conceptual architecture of bioelectric regulation

To integrate these findings, I propose the following model of interacting control systems:

Level 1: The cellular bioelectric state. Every living cell maintains a resting membrane potential a voltage difference across its plasma membrane typically in the range of -10 to -90 mV. These potentials form a continuous state space that determines cell behavior in a predictable, modular fashion: proliferate, differentiate, migrate, or remain quiescent (Blackiston et al., 2009).

Level 2: Tissue-level bioelectric circuits. Cells are electrically coupled to their neighbors via gap junctions, forming continuous electrical syncytia. The spatial distribution of Vmem across a tissue constitutes a bioelectric circuit carrying information about the global topology of the organism, enabling the tissue to maintain stable configurations against perturbation (Mathews & Levin, 2017).

Level 3: The morphogenetic field. The spatiotemporal pattern of bioelectric potentials across a developing or regenerating tissue encodes the "target morphology." This is not a separate, immaterial entity but a physical, measurable distribution of electrical potentials whose causal properties are field-like (Durant et al., 2019).

Level 4: Organismic integration. The bioelectric state of individual tissues is embedded within the larger physiological context of the whole organism through endogenous electromagnetic fields and systemic ionic milieu.

3.3 Bioelectric regulation in adult metabolic tissues: bridging the developmental-metabolic gap

A legitimate concern arises regarding the extrapolation of bioelectric principles from developmental and regenerative systems to adult metabolic physiology. The strongest demonstrations of large-scale bioelectric pattern control derive from planarian regeneration, amphibian embryogenesis, and cancer suppression models contexts in which whole-anatomy patterning decisions are at stake. The question of whether adult insulin-sensitive tissues retain the capacity for bioelectrically regulated state transitions of the kind observed in these developmental systems is an empirical one that remains open.

It should be acknowledged at the outset that the bridge between developmental bioelectricity and adult metabolic physiology is constructed from plausibility arguments rather than direct experimental demonstration. The present framework does not require adult skeletal muscle, adipose tissue, or liver to exhibit embryonic-scale morphogenetic bioelectric fields with long-range spatial patterning and binary cell-fate determination. What it requires is substantially more modest: that these tissues possess the capacity for stable, local shifts in resting membrane potential sufficient to alter signaling thresholds and membrane-associated biochemical kinetics. This capacity is well-established. Adult metabolic tissues express a rich repertoire of ion channels including voltage-gated sodium, calcium, and potassium channels, inwardly rectifying potassium channels, chloride channels, and non-selective cation channels whose expression and activity are dynamically regulated by hormonal, metabolic, and neural inputs. Gap junction coupling, mediated by connexin proteins with tissue-specific isoform expression, provides the anatomical substrate for local electrical syncytia. The autonomic nervous system, circulating catecholamines, and endocrine factors including insulin itself modulate ion channel phosphorylation states and membrane potential. Sustained alterations in any of these inputs can

produce persistent shifts in local tissue Vmem without invoking the elaborate pattern-forming dynamics of embryogenesis.

The framework thus builds on the same biophysical principles ion channel regulation of membrane potential, gap junction-mediated electrical coupling, and the modulation of protein conformation by local electric fields that operate in development, but applies them to the more constrained regulatory context of adult metabolic tissue. Whether these principles translate into functionally significant Vmem shifts in the specific context of insulin resistance is precisely the empirical question that the predictions in Section 4.5 are designed to address.

3.4 Limits of extrapolation

It is essential to acknowledge a significant limitation. The most robust evidence for bioelectric control derives from embryogenesis, regeneration, and tumor regulation contexts involving pattern formation and large-scale anatomical decisions. The extrapolation of this framework to chronic metabolic disease, particularly type 2 diabetes, remains hypothetical and requires direct experimental validation. The present argument should therefore be interpreted not as an established explanatory model but as a mechanistic proposal whose central virtue is the generation of specific, falsifiable predictions.

3.5 Hierarchical organization of bioelectric regulation

The multi-level architecture of bioelectric regulation can be rendered schematically to clarify the physical basis and biological function of each organizational stratum.

Table 2. Hierarchical model of bioelectric and informational regulation

Regulatory level	Physical basis	Biological function	Selected evidence
Cellular	Resting membrane potential (Vmem), ion channel expression	Cell-fate decisions (proliferate vs. quiesce, stem vs. differentiated)	Levin, 2021; Blackiston et al., 2009
Syncytial	Gap junction coupling, tissue-level voltage gradients	Spatial patterning, coordinated multicellular behavior	Mathews & Levin, 2017
Morphogenetic	Spatiotemporal bioelectric pattern across a developing field	Encoding of anatomical target morphology	Durant et al., 2019; Tseng & Levin, 2013
Organismic	Endogenous electromagnetic fields, systemic ionic milieu	Global physiological coordination, chronobiological regulation	Burr, 1972

4. Insulin resistance: a bioelectric re-evaluation

4.1 The standard model and Its explanatory gaps

Type 2 diabetes is defined by elevated blood glucose in the context of insulin resistance. The standard biochemical model of insulin resistance centers on defects in the insulin signaling cascade: impaired autophosphorylation of the insulin receptor, reduced tyrosine phosphorylation of IRS-1, increased inhibitory serine phosphorylation of IRS-1, reduced PI3K activation, impaired Akt-mediated translocation of GLUT4 to the plasma membrane, and consequent reduction in glucose uptake (Petersen & Shulman, 2018).

This model is descriptively accurate but etiologically proximate. It tells us *how* insulin resistance is implemented at the molecular level, but it does not explain *why* the signaling cascade becomes impaired. The standard upstream explanations "lipotoxicity," "ectopic fat accumulation," "mitochondrial dysfunction," "endoplasmic reticulum stress" push the question back one step without resolving it.

Furthermore, several empirical observations sit uncomfortably within a purely cell-autonomous, bottom-up model. Insulin resistance does not develop uniformly across all insulin-sensitive tissues. In morbidly obese patients undergoing bariatric surgery, hepatic insulin sensitivity normalizes within days, before significant weight loss occurs a temporal pattern difficult to reconcile with chronic lipid accumulation (Taylor, 2013). The phenomenon of "metabolic memory" in which prior hyperglycemia confers persistent risk of complications despite subsequent normoglycemia suggests a lasting alteration in tissue state not captured by current molecular markers (Holman et al., 2008).

4.2 The bioelectric hypothesis: a constraint-based perspective

I propose the following, testable hypothesis: Insulin resistance may be importantly sustained by a pathological alteration of the resting membrane potential (Vmem) of insulin-sensitive cells. This bioelectric state acts as a system-level constraint that renders the molecular signaling machinery less capable of responding to insulin, not because the machinery is intrinsically defective, but because the electrical context in which it operates has been altered.

This is a claim about multi-level causation. The molecular pathology is real, but it may be consequential to, or stabilized by, a higher-order bioelectric state. The relationship is one of reciprocal constraint, not unidirectional bottom-up determination. Once established, a tissue-level Vmem pattern can become self-reinforcing through gap junction-mediated feedback

loops. The "metabolic memory" phenomenon would thus be explained as a form of bioelectric hysteresis a persistent electrical memory of prior hyperglycemia encoded in the tissue's membrane potential.



Figure 1. A bioelectric systems framework for insulin resistance: mechanistic pathways linking membrane potential dysregulation to molecular pathology. The schematic integrates the four proposed pathways by which sustained membrane depolarization may impair insulin signaling. Primary metabolic and inflammatory insults (Panel A) converge on a less negative resting membrane potential (Vmem). This bioelectric perturbation propagates through four distinct but complementary routes: (1) electrostatic modulation of the insulin receptor tyrosine kinase, reducing ligand-induced autophosphorylation; (2) voltage-gated calcium channel-mediated Ca^{2+} influx, with subsequent PKC/CaMKII-dependent inhibitory serine phosphorylation of IRS-1; (3) Vmem-dependent disruption of GLUT4 vesicle trafficking and SNARE-mediated exocytosis; and (4) plasma–mitochondrial membrane potential coupling, wherein sustained depolarization compromises mitochondrial calcium handling and bioenergetic efficiency, generating ROS that further inhibit insulin signaling at multiple nodes. These pathways converge on a multi-node impairment of insulin action, producing the metabolic manifestations of systemic insulin resistance, which in turn reinforce the initial depolarizing insults through biomechanical metabolic feedback loops (Panel D). The figure thus serves as a graphical roadmap for the mechanistic architecture developed in Section 4.3.

4.3 A mechanistic bridge: from membrane potential to insulin signaling

A critical requirement for this hypothesis is a plausible mechanistic bridge a set of intermediary processes by which a shift in Vmem could produce or sustain the known molecular signature of insulin resistance. Drawing on principles of biophysical chemistry and molecular electrophysiology, I propose four non-mutually exclusive pathways, each specified at the level of molecular interactions and experimentally tractable.

4.3.1 Electrostatic modulation of the insulin receptor tyrosine kinase

The insulin receptor is a heterotetrameric transmembrane glycoprotein belonging to the receptor tyrosine kinase (RTK) superfamily. Its activation mechanism involves insulin binding to the extracellular α-subunits, inducing a conformational change transmitted across the plasma membrane to the intracellular β-subunit kinase domains. This conformational transmission may be sensitive to the local dielectric environment of the lipid bilayer and the transmembrane electric field, though direct evidence for voltage-dependent gating of the insulin receptor analogous to that established for voltage-gated ion channels is not yet available. The following account should therefore be read as a mechanistically motivated hypothesis, not a description of established fact.

From a chemical perspective, the conformational equilibrium of the insulin receptor kinase domain is governed by the free energy difference (ΔG) between inactive and active states. The transmembrane potential may contribute to this free energy landscape through the interaction of the membrane electric field with charged and dipolar residues within the receptor's transmembrane and juxtamembrane regions. A typical resting membrane potential of approximately -70 mV generates an electric field of roughly 10^7 V/m across the 4-5 nm hydrophobic core of the lipid bilayer a field strength sufficient to orient dipoles, shift pKa values of titratable residues by up to 2-3 units, and alter the energy barriers separating conformational substates (Bezanilla, 2008). While this principle is well-established for voltage-sensing domains of ion channels, its applicability to the insulin receptor remains to be empirically determined.

Sustained depolarization a shift, for example, from -70 mV to -40 mV would reduce the transmembrane electric field by approximately 40%. Such a reduction could, in principle, alter the electrostatic free energy profile of the receptor's conformational landscape. The insulin

receptor's intracellular juxtamembrane region contains a conserved NPXY motif and adjacent basic residues that participate in electrostatic interactions with anionic phospholipid headgroups (specifically phosphatidylinositol 4,5-bisphosphate, PIP2) on the inner leaflet. These interactions may be voltage-sensitive because the orientation of the receptor's cytoplasmic domains relative to the membrane plane is modulated by the transmembrane field. Depolarization may weaken this orienting constraint, potentially increasing the entropic penalty for adopting the precise active conformation required for trans-autophosphorylation of the kinase activation loop at residues Tyr1158, Tyr1162, and Tyr1163 (Hubbard, 2013).

A plausible chemical consequence of depolarization would therefore be a shift in the conformational equilibrium of the receptor not through covalent modification, but through an electrostatic mechanism. This would manifest experimentally as reduced insulin-stimulated autophosphorylation without any change in receptor expression, ligand binding affinity at equilibrium, or primary sequence. This prediction is testable using voltage-clamped cells expressing wild-type insulin receptors, with phosphorylation stoichiometry measured by quantitative phosphotyrosine Western blotting or mass spectrometry.

4.3.2 Voltage-gated calcium channel tone and IRS-1 serine phosphorylation

Membrane depolarization, even sub-threshold depolarizations that do not trigger action potentials, increases the open probability (Po) of voltage-gated calcium channels (VGCCs). In hepatocytes and adipocytes, the L-type channels Cav1.2 and Cav1.3 are the dominant isoforms coupling membrane voltage to calcium influx, and their slow inactivation kinetics permit a sustained trickle of calcium entry during prolonged depolarization. In skeletal muscle, the principal L-type channel is Cav1.1, which functions primarily as a voltage sensor for excitation–contraction coupling via allosteric activation of the ryanodine receptor (RyR1) rather than as a significant calcium-conducting pore. The identity of the channel subtype mediating any depolarization-induced calcium entry in adult skeletal muscle therefore remains unsettled. T-type channels (Cav3.1, Cav3.2) activate at more hyperpolarized voltages, yet their rapid and complete inactivation at sustained depolarized potentials makes them unlikely mediators of a chronic calcium leak. Store-operated calcium entry (SOCE) via STIM1–Orai1, which is triggered by sarcoplasmic reticulum calcium depletion and is voltage-independent, has been documented in mature skeletal muscle and represents a plausible complementary route for sustained, low-grade calcium elevation in this tissue, potentially coupled to depolarization through Cav1.1-dependent alterations in sarcoplasmic reticulum calcium homeostasis, though

this indirect link remains to be experimentally demonstrated. The relationship between membrane potential and VGCC open probability follows a Boltzmann distribution, meaning that in hepatocytes and adipocytes at least—a sustained depolarization of even 10–15 mV can shift a small but physiologically significant fraction of L-type channels from the closed to the open state.

The resulting chronic, low-grade elevation of intracellular calcium concentration ($[Ca^{2+}]i$) not the large transient spikes characteristic of excitation-contraction coupling, but a sustained elevation from the typical basal level of approximately 100 nM to perhaps 150-200 nM is sufficient to alter the activity of calcium-dependent enzymes. Two enzyme families are of particular relevance:

Protein kinase C (PKC). The conventional PKC isoforms (α, βI, βII, γ) require both calcium and diacylglycerol (DAG) for full activation. Elevated $[Ca^{2+}]i$ increases the membrane association of these isoforms, enhancing their sensitivity to DAG generated by basal phospholipid metabolism. Once activated, PKC phosphorylates IRS-1 on Ser307 (in rodents; Ser312 in humans) the prototypical inhibitory phosphorylation site as well as adjacent serine residues including Ser612 and Ser636/639 (Boura-Halfon & Zick, 2009). Phosphorylation at Ser307 sterically inhibits the interaction between IRS-1 and the insulin receptor's phosphotyrosine-binding (PTB) domain, while also promoting IRS-1 degradation via the ubiquitin-proteasome pathway.

Calcium/Calmodulin-dependent protein kinase II (CaMKII). Sustained elevation of $[Ca^{2+}]i$ promotes the calcium-saturated calmodulin (Ca^{2+}/CaM)-dependent activation and autophosphorylation of CaMKII at Thr287, rendering the kinase calcium-independent. CaMKII directly phosphorylates IRS-1 on Ser307 as well as on additional serine residues, and has been implicated in the impairment of insulin-stimulated glucose uptake in skeletal muscle (Ozcan et al., 2013).

This pathway provides a biophysically and biochemically well-characterized link from a bioelectric state (depolarization) to a central molecular lesion (IRS-1 serine phosphorylation). The chemistry is precisely defined: the increase in calcium occupancy of the EF-hand motifs of calmodulin (Kd approximately 10^{-6} M), the calcium-dependent membrane translocation of PKC via its C2 domain, and the subsequent ATP-dependent phosphotransfer from the kinase active site to the serine hydroxyl of the IRS-1 substrate. Critically, this mechanism predicts that pharmacological blockade of L-type calcium channels (e.g., with verapamil or nifedipine) should partially restore insulin sensitivity in depolarized cells, a prediction that can be tested independently of other metabolic perturbations.

4.3.3 GLUT4 vesicle trafficking and membrane electrostatics

The final, rate-limiting step in insulin-stimulated glucose uptake is the translocation of GLUT4-containing vesicles from intracellular compartments to the plasma membrane, followed by vesicle docking, SNARE-mediated fusion, and insertion of GLUT4 transporters into the membrane. Each of these steps involves electrostatic interactions whose sensitivity to membrane potential is plausible but not yet directly demonstrated for the GLUT4 trafficking machinery specifically. The following account therefore offers a mechanistically motivated hypothesis rather than an established pathway.

The plasma membrane's inner leaflet is enriched in anionic phospholipids, particularly phosphatidylserine (PS) and PIP2, which create a negative surface potential (typically -20 to -40 mV). GLUT4 vesicles possess a similarly charged surface. The approach of a negatively charged vesicle to a negatively charged membrane surface encounters an electrostatic repulsive barrier. Under normal physiological conditions, the resting membrane potential contributes to the transmembrane voltage that orients membrane dipole potentials and concentrates cations (particularly Ca^{2+} and Mg^{2+}) at the membrane surface, screening the negative surface charge and facilitating close membrane apposition.

Depolarization may alter local ionic screening and the effective surface potential, potentially modifying the electrostatic energy barrier for vesicle docking. The Debye screening length in physiological saline is approximately 0.8 nm; a vesicle approaching within 1-2 nm of the plasma membrane experiences an electrostatic repulsion that depends exponentially on the surface potential. Even a 10-15 mV change in the surface potential could, in principle, alter the probability of SNARE complex formation the four-helix bundle formed by syntaxin-4, SNAP-23, and VAMP2 that catalyzes vesicle fusion by changing the local concentration and orientation of these proteins at the docking site (Bryant et al., 2002; Jahn & Fasshauer, 2012).

In depolarized cells, therefore, GLUT4 translocation may be impaired even when the upstream signaling cascade (IRS-1 → PI3K → Akt → AS160/TBC1D4 phosphorylation) is functional. This mechanism predicts that direct measurement of GLUT4 at the plasma membrane by subcellular fractionation, immunofluorescence with surface-specific antibodies, or TIRF microscopy would reveal reduced insertion despite normal Akt phosphorylation, a pattern distinct from what is observed with PI3K inhibition.

4.3.4 Mitochondrial membrane potential coupling

The plasma membrane potential (Vmem) and the mitochondrial inner membrane potential ($\Delta\Psi m$) are bioenergetically coupled. The Na^+/K^+-ATPase maintains Vmem at the cost of ATP hydrolysis; the F_1F_o-ATP synthase generates ATP driven by the proton motive force across the mitochondrial inner membrane. This coupling is not merely thermodynamic but also ionic: cytoplasmic calcium, sodium, and potassium concentrations influence both membrane potentials, and the two compartments communicate through the exchange of ions and metabolites across the mitochondrial membranes.

Sustained plasma membrane depolarization alters the driving force for ion transport across both membranes. In particular, reduced Na^+ gradient across the plasma membrane (due to partial depolarization) reduces the activity of the mitochondrial Na^+/Ca^{2+} exchanger, leading to altered mitochondrial calcium handling. Mitochondrial calcium is a key regulator of the tricarboxylic acid (TCA) cycle, activating pyruvate dehydrogenase, isocitrate dehydrogenase, and α-ketoglutarate dehydrogenase all rate-limiting enzymes of oxidative metabolism (Denton, 2009). Disruption of mitochondrial calcium homeostasis by sustained plasma membrane depolarization could thus impair substrate oxidation and contribute to the intramyocellular lipid accumulation characteristic of insulin-resistant skeletal muscle the very "lipotoxicity" often invoked as a primary cause in the standard model, but which may itself be a downstream consequence of a bioelectric perturbation.

4.3.5 Relative plausibility and hierarchical organization of the pathways

The four pathways presented above are not equally supported by existing evidence, and it is important to distinguish their relative standing. The VGCC/PKC/CaMKII pathway (Section 4.3.2) has the strongest empirical foundation: the molecular identity of the channels is known, their expression in insulin-sensitive tissues is documented, the calcium dependence of PKC and CaMKII activation is biochemically characterized, and the phosphorylation of IRS-1 on Ser307 by these kinases is a canonical feature of insulin resistance. The mitochondrial coupling pathway (Section 4.3.4) is supported by well-established principles of bioenergetics, though direct evidence for Vmem→$\Delta\Psi m$ coupling specifically in the context of insulin resistance is sparse. The electrostatic modulation pathway (Section 4.3.1) and the GLUT4 trafficking hypothesis (Section 4.3.3) are the most speculative. While the biophysical principles invoked are sound, neither insulin receptor voltage sensitivity nor membrane potential-dependent GLUT4 vesicle docking has been experimentally demonstrated in any context. These pathways

are included not because they are equally probable, but because they are equally testable, and their inclusion defines a landscape of experimental questions that extends beyond the most obvious candidate mechanisms.

For the purposes of experimental prioritization, the VGCC pathway should be considered the leading candidate, with the mitochondrial, electrostatic, and trafficking pathways representing progressively more speculative but mechanistically complementary alternatives. The value of specifying all four is that they are empirically distinguishable: a depolarization-induced impairment of insulin signaling that is fully rescued by verapamil implicates the VGCC pathway; one that is not rescued by verapamil but is accompanied by reduced Akt-independent GLUT4 insertion implicates the trafficking pathway; one that alters both insulin signaling and substrate oxidation implicates mitochondrial coupling.

4.4 Objections and alternative explanations

Any mechanistic proposal in complex chronic disease must contend with alternative models. Three major frameworks warrant explicit consideration.

Objection 1: The inflammation-first model. Pro-inflammatory cytokines such as TNF-α and IL-6 activate stress kinases, including JNK and IKK, which phosphorylate IRS-1 on inhibitory serine residues (Hotamisligil, 2006). In this model, bioelectric changes would be downstream consequences of inflammatory signaling.

Response: These models need not be incompatible. Inflammatory cytokines modulate ion channel expression and activity TNF-α alters potassium channel function in multiple cell types. It is plausible that chronic inflammation produces insulin resistance *in part through* the bioelectric mechanisms described above, with Vmem depolarization serving as a convergent biophysical pathway through which diverse inflammatory insults produce a common molecular phenotype. However, this very compatibility represents a limitation of the present framework: a theory that is compatible with all competing explanations risks lacking discriminatory power. To address this, the bioelectric hypothesis makes specific predictions about the temporal sequence of events. If Vmem depolarization is a mediator of inflammation-induced insulin resistance, then experimental induction of inflammation should produce measurable Vmem depolarization *before* the development of insulin resistance, and pharmacological normalization of Vmem should rescue insulin sensitivity even in the continued presence of inflammatory stimuli. If, conversely, Vmem depolarization is merely a downstream epiphenomenon of

inflammation, then normalizing Vmem should not rescue insulin sensitivity when inflammatory signaling remains active. These are empirically distinguishable scenarios.

Objection 2: The mitochondrial dysfunction model. Reduced oxidative capacity and impaired fatty acid oxidation drive ectopic lipid accumulation and insulin resistance. Here, insulin resistance is a problem of cellular energetics, not electrical signaling (Petersen & Shulman, 2018).

Response: As argued in Section 4.3.4, the plasma and mitochondrial membrane potentials are reciprocally coupled. The two models may describe the same system from different vantage points: one emphasizing metabolic output, the other electrical input. The critical empirical question is whether Vmem changes precede or follow mitochondrial dysfunction. Longitudinal studies in animal models of diet-induced insulin resistance, with simultaneous measurement of Vmem, $\Delta\Psi m$, and insulin sensitivity, could address this question. If Vmem depolarization precedes measurable mitochondrial dysfunction, the bioelectric model gains explanatory priority; if mitochondrial dysfunction precedes Vmem changes, the reverse obtains.

Objection 3: The autonomic dysregulation model. Increased sympathetic tone and reduced parasympathetic tone drive peripheral insulin resistance through neural and neuroendocrine pathways.

Response: The autonomic nervous system communicates with peripheral tissues through neurotransmitters that bind to G-protein coupled receptors, which in turn modulate ion channel activity and membrane potential. A chronic increase in sympathetic tone could depolarize insulin-sensitive tissues through adrenergic receptor-mediated effects on potassium and calcium channels. The bioelectric framework thus offers a plausible peripheral mechanism through which central autonomic signals are transduced into stable changes in tissue insulin sensitivity.

4.5 Testable predictions



Figure 2. Falsifiable predictions roadmap for the bioelectric mechanisms of insulin resistance. The table operationalizes each of the four mechanistic pathways as a set of experimentally tractable predictions, specifying the independent variable (bioelectric perturbation), the mediating mechanistic readout, the dependent systems-level outcome, the appropriate experimental or clinical model, and the key measurement modalities. A dedicated column identifies the disconfirming outcome that would refute each prediction, thereby embedding falsifiability into the architecture of the framework. General cross-cutting predictions (e.g., correlation between Vmem depolarization and insulin resistance severity) and human translational predictions (e.g., Vmem as a predictive biomarker) are summarized below the main table. A phased testing roadmap from feasibility (Phase 1) through mechanistic validation (Phases 2–3) to clinical translation (Phase 4) is appended to guide future experimental programs. The full content of each prediction is elaborated in the text of Section 4.5.

The bioelectric hypothesis generates specific, falsifiable predictions. The following assessment distinguishes between predictions that are, in principle, testable and those for which current technology provides a realistic path to experimental implementation.

Prediction 1: Insulin-resistant skeletal muscle and adipose tissue will exhibit a depolarized resting membrane potential compared to insulin-sensitive tissue from matched controls. *Testability:* High in principle; considerable technical challenges in vivo. Microelectrode impalement of intact human skeletal muscle is feasible in research settings but requires surgical

exposure and is not suitable for large-scale studies. Voltage-sensitive dye imaging of needle biopsy specimens offers a more practical alternative, though it sacrifices the in vivo electrical context. Surface electromyographic or impedance-based techniques, while non-invasive, lack the spatial resolution to resolve Vmem at the cellular level. The most realistic initial approach would employ rodent models of diet-induced insulin resistance, where Vmem measurements can be performed under controlled conditions with terminal microelectrode recordings.

Prediction 2: The magnitude of Vmem depolarization will correlate quantitatively with the severity of insulin resistance, as measured by clamp-derived glucose disposal rates. *Testability:* Contingent on successful implementation of Prediction 1. If reliable Vmem measurement is achieved, the correlation analysis is straightforward.

Prediction 3: Experimental depolarization of insulin-sensitive cells, via pharmacological blockade of potassium channels (e.g., with 4-aminopyridine or tetraethylammonium), will acutely induce insulin resistance as measured by reduced insulin-stimulated 2-deoxyglucose uptake, in the absence of any other metabolic perturbation. *Testability:* High in isolated cell systems (C2C12 myotubes, 3T3-L1 adipocytes, primary hepatocytes). A significant experimental caveat is that 4-aminopyridine is a potent neurotoxin at micromolar concentrations and its chronic administration in vivo is precluded by seizure risk. For in vivo experiments, alternative strategies such as optogenetic depolarization using channelrhodopsin variants expressed under tissue-specific promoters would provide greater specificity and temporal control, though these approaches introduce their own technical complexities.

Prediction 4: Experimental hyperpolarization of insulin-resistant cells, via pharmacological activation of potassium channels (e.g., with pinacidil or diazoxide), will restore insulin sensitivity. This restoration should be blocked by pre-treatment with the K_ATP channel blocker glibenclamide, confirming specificity. *Testability:* High in isolated cells. Pinacidil and diazoxide are clinically used agents (for hypertension and hyperinsulinism, respectively), providing a translational path. The glibenclamide blockade control is straightforward in cell culture.

Prediction 5: The "metabolic memory" phenomenon will be associated with persistent Vmem depolarization in previously hyperglycemic tissues. Experimental normalization of Vmem will abolish this legacy effect. *Testability:* This is the most experimentally demanding prediction. It requires a longitudinal animal model with controlled induction and reversal of hyperglycemia, repeated Vmem measurements over time, and a demonstration that Vmem normalization achieved without altering glycemic status eliminates the legacy risk. The definition of "Vmem normalization" is itself non-trivial: does one aim for the pre-hyperglycemic Vmem value, a

population average, or a functionally defined threshold? These operational parameters must be established empirically.

Prediction 6: Magnesium supplementation, which supports Na^+/K^+-ATPase function and stabilizes membrane potential, will improve insulin sensitivity in magnesium-deficient subjects. The magnitude of improvement will correlate with the degree of Vmem normalization, as measured by non-invasive techniques such as buccal mucosal potential difference. *Testability:* This is the prediction closest to clinical feasibility. Magnesium supplementation trials are low-risk, and buccal mucosal potential difference measurement is a non-invasive, albeit indirect, assessment of tissue membrane potential. The major confound is that magnesium has pleiotropic effects it serves as a cofactor for hundreds of enzymatic reactions and attributing any observed improvement in insulin sensitivity specifically to Vmem normalization will require careful experimental design, including measurement of intracellular free magnesium concentration (^{31}P-NMR or mag-fura-2) and Vmem in parallel with metabolic outcomes.

4.6 The role of Magnesium: a chemical and electrical bridge

Magnesium (Mg^{2+}) occupies an instructive position at the nexus of biochemistry and bioelectricity. Chemically, Mg^{2+} is the most abundant divalent cation in the intracellular milieu, with a free concentration in the cytoplasm of approximately 0.5-1.0 mM and a total cellular concentration of 15-20 mM when bound to ATP, nucleic acids, and proteins. Its ionic radius (0.72 Å) is significantly smaller than those of Na^+ (1.02 Å), K^+ (1.38 Å), or Ca^{2+} (1.00 Å), giving it an exceptionally high charge density that underpins its unique coordination chemistry. Mg^{2+} serves as an obligatory cofactor for all enzymes that utilize ATP, because the true substrate is not ATP^{4-} but the $MgATP^{2-}$ complex. The Na^+/K^+-ATPase the electrogenic pump that establishes the resting membrane potential by exporting three Na^+ ions and importing two K^+ ions per ATP hydrolyzed is thus fundamentally a magnesium-dependent enzyme. The pump's α-subunit contains a Mg^{2+} binding site in the phosphorylation (P) domain; without Mg^{2+} coordination to the Asp369 residue, the E1 → E2 conformational transition that drives ion translocation cannot proceed (Morth et al., 2007).

Magnesium also directly modulates membrane potential through its interaction with potassium channels. Intracellular Mg^{2+} blocks the outward flow of K^+ through inwardly rectifying potassium channels (Kir channels) by binding to a site within the channel pore, a mechanism known as "intrinsic inward rectification." This Mg^{2+} block is voltage-dependent: depolarization drives Mg^{2+} deeper into the pore, enhancing block and reducing K^+ efflux, thus contributing to

the stabilization of the resting membrane potential near the K^+ equilibrium potential. In magnesium deficiency, reduced Mg^{2+} block of Kir channels results in excessive K^+ efflux, paradoxically contributing to membrane depolarization rather than hyperpolarization because of secondary effects on the Na^+/ K^+-ATPase electrogenic potential.

Epidemiological evidence consistently demonstrates strong associations between magnesium deficiency and insulin resistance, type 2 diabetes, and metabolic syndrome, with meta-analyses of prospective cohort studies showing a 15-23% reduction in type 2 diabetes risk per 100 mg/day increment in dietary magnesium intake (Fang et al., 2016; Barbagallo & Dominguez, 2015). The standard interpretation attributes this association to magnesium's role as an enzymatic cofactor in the insulin signaling cascade. I propose, as a complementary and mechanistically specified hypothesis, that magnesium deficiency contributes to insulin resistance by impairing Na^+/K^+-ATPase activity and reducing Kir channel block, leading to a sustained depolarization of the resting membrane potential of insulin-sensitive tissues. This proposal is directly testable through combined measurement of tissue Vmem, clamp-derived insulin sensitivity, and intracellular free magnesium concentration (by ^{31}P-NMR spectroscopy or mag-fura-2 fluorescence) before and after controlled magnesium supplementation.

4.7 The central empirical gap

It must be stated explicitly that no direct in vivo mapping currently establishes persistent Vmem depolarization in insulin-resistant human skeletal muscle, adipose tissue, or liver. The absence of such data constitutes the central empirical gap the present framework identifies. The technical challenges are significant: accurate measurement of resting membrane potential in intact tissues requires microelectrode impalement or voltage-sensitive dye imaging under conditions that preserve the in vivo bioelectric state conditions that are difficult to achieve in clinical settings. However, the development of non-invasive or minimally invasive techniques for tissue Vmem assessment including surface potential mapping, impedance spectroscopy, and novel voltage-sensitive fluorescent probes compatible with needle biopsy specimens represents precisely the research agenda that the bioelectric framework motivates. The value of a mechanistic hypothesis is not merely in its confirmation, but in its capacity to define the experiments that must be performed.

4.8 Toward an initial experimental design: a proposed conspectus

While a fully specified experimental protocol is beyond the scope of a theoretical paper and would require the input of specialists in electrophysiology, metabolic physiology, and clinical investigation, it is appropriate to outline, in broad strokes, the design of the experiments most likely to advance or refute the bioelectric hypothesis. The most critical initial experiment is the direct measurement of Vmem in insulin-sensitive tissues from an established animal model of insulin resistance the high-fat diet (HFD)-fed C57BL/6 mouse being the most extensively characterized. Skeletal muscle (extensor digitorum longus or soleus) and liver would be the primary tissues of interest. Resting membrane potential would be measured by conventional intracellular microelectrode recording in freshly isolated, superfused tissue maintained at 37°C in oxygenated Krebs-Henseleit buffer. Insulin sensitivity would be assessed in the same animals by hyperinsulinemic-euglycemic clamp, and the correlation between Vmem and glucose disposal rate would be the primary endpoint. A positive finding a statistically significant correlation between Vmem depolarization and insulin resistance would justify the more complex experiments outlined in Predictions 3-5. A negative finding would substantially weaken, though not necessarily refute, the bioelectric hypothesis, as it would leave open the possibility that Vmem changes are regionally heterogeneous, dynamically unstable ex vivo, or manifest only under specific metabolic conditions not captured by the experimental design.

For the translational prediction regarding magnesium, a double-blind, placebo-controlled crossover trial in magnesium-deficient subjects with insulin resistance (defined by clamp), measuring tissue Vmem (buccal mucosa), intracellular magnesium, and clamp-derived insulin sensitivity before and after eight weeks of controlled magnesium supplementation versus placebo, represents a feasible and informative clinical experiment. Such a trial would not only test Prediction 6 but would also provide the first direct evidence or refutation of a causal relationship between membrane potential and insulin sensitivity in humans.

5. Philosophical dimensions: causation and ontology

5.1 Beyond mechanism and vitalism

The argument developed in this paper occupies a philosophical position distinct from both classical mechanism and classical vitalism. It rejects the ontological reductionism that reduces the organism to its molecular components, but equally rejects the notion of an immaterial "life force" beyond scientific scrutiny. The position advanced here is an organismic-systems

ontology recognizing the causal efficacy of higher-order organizational patterns without reifying them into separate ontological substances.

This position resonates with the "organicism" of Joseph Needham (1936), the "integrative levels" concept of J. S. Haldane (1931), and most powerfully with Denis Noble's "principle of biological relativity," which holds that there is no privileged level of causation in biological systems (Noble, 2012, 2017). Noble articulates a form of constraint-based downward causation: system-level organization acts as a set of boundary conditions constraining the dynamics of lower-level components. A cell's Vmem, influenced by its neighbors and systemic physiology, does not force the insulin receptor to malfunction. It constrains the receptor's conformational and kinetic landscape such that a normal response to insulin is probabilistically disfavored. This is a physical, mathematically modelable relationship (Ellis, 2016).

5.2 The epistemological challenge of complex systems

The reductionist strategy works when systems are "nearly decomposable" (Simon, 1962) when component interactions are weak enough that behavior in isolation approximates behavior in the intact system. Living organisms in chronic disease are not nearly decomposable. Interactions are strong, non-linear, and multiply connected. The insulin receptor's behavior depends on membrane lipid composition, local pH, redox state, interacting proteins, and as argued here the electrical potential across the membrane.

This epistemic limitation is not a temporary gap to be filled by more data; it is a structural feature of complex adaptive systems demanding a correspondingly sophisticated epistemology: mechanistic explanation must be supplemented with dynamical explanation; prediction is inherently limited but probabilistic; and therapeutic logic must shift from fixing broken molecular parts to restoring functional dynamics of the whole system.

6. Institutional dimensions and the path forward

6.1 The inertia of a dominant paradigm

The biochemical paradigm is sustained by an interlocking system of institutional incentives: funding structures rewarding molecular granularity over systemic integration, publication norms favoring mechanistic novelty over clinical restoration of health, regulatory frameworks designed primarily for single-molecule interventions, and medical education minimizing

training in electrophysiology and complex systems theory. These structural factors represent the normal institutionalization of a paradigm that, for a certain class of problems, has been extraordinarily successful. The difficulty is that this very success has produced a rigidity preventing the system from recognizing the limitations of its own model when confronting complex chronic disease.

6.2 Toward a responsible methodological pluralism

The position advocated here is not a dogmatic replacement of biochemistry with bioelectricity. It is a call for responsible ontological and methodological pluralism: enriching the standard biomedical model by integrating bioelectric and systems-level perspectives as fundamental expansions to the underlying ontology; developing research methodologies appropriate for non-linear regulatory systems; and reforming medical education to equip future physicians to think beyond the molecular paradigm while retaining its genuine achievements. The ultimate aim is a medicine that rigorously investigates all levels of biological organization, holding every claim to the same standards of falsifiable, empirically grounded inquiry.

7. Conclusion: toward disciplined expansion

Current evidence suggests important limitations in models of chronic disease grounded exclusively in molecular reductionism. The metabolic, autoimmune, neurodegenerative, and chronic inflammatory conditions dominating the disease burden of the twenty-first century are diseases of regulation emergent properties of a complex, multi-level system whose behavior resists explanation purely in the language of genes, proteins, and metabolites. The bioelectric framework advanced here offers a disciplined expansion of the existing paradigm, recognizing membrane potential gradients and endogenous fields as an underexplored physical language of physiological control. The case study of insulin resistance provides a concrete illustration: a chemically specified mechanistic bridge, a series of testable predictions that explicitly acknowledge their own technical limitations, an honest engagement with alternative models that recognizes the tension between integrative compatibility and explanatory specificity, and a frank acknowledgment of the central empirical gap.

It must be conceded that the bridge from developmental bioelectricity to adult metabolic physiology, as argued in Section 3.3, is constructed from plausibility arguments rather than direct experimental evidence. The ion channel repertoire of adult tissues, the capacity for gap

junction-mediated electrical coupling, and the modulation of membrane potential by hormonal and neural inputs are well-documented facts, but whether these elements cohere into functionally significant Vmem shifts specifically in the context of insulin resistance remains an open empirical question. The framework thus stands as a structured proposal for investigation, not a summary of established findings.

Whether the bioelectric hypothesis is ultimately confirmed, refuted, or incorporated into a more comprehensive synthesis, the investigation will have served its purpose by opening new experimental and conceptual territory in the effort to understand and address complex chronic disease.

References

Barbagallo, M., & Dominguez, L. J. (2015). Magnesium and type 2 diabetes. *World Journal of Diabetes*, 6(10), 1152-1157. https://doi.org/10.4239/wjd.v6.i10.1152

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M., ... & Tall, A. R. (2007). Effects of torcetrapib in patients at high risk for coronary events. *New England Journal of Medicine*, 357(21), 2109-2122. https://doi.org/10.1056/NEJMoa0706628

Bezanilla, F. (2008). How membrane proteins sense voltage. *Nature Reviews Molecular Cell Biology*, 9(4), 323-332. https://doi.org/10.1038/nrm2376

Blackiston, D. J., McLaughlin, K. A., & Levin, M. (2009). Bioelectric controls of cell proliferation: Ion channels, membrane voltage and the cell cycle. *Cell Cycle*, 8(21), 3527-3536. https://doi.org/10.4161/cc.8.21.9888

Boura-Halfon, S., & Zick, Y. (2009). Phosphorylation of IRS proteins, insulin action, and insulin resistance. *American Journal of Physiology-Endocrinology and Metabolism*, 296(4), E581-E591. https://doi.org/10.1152/ajpendo.90437.2008

Brigandt, I., & Love, A. (2017). Reductionism in biology. In E. N. Zalta (Ed.), *The Stanford Encyclopedia of Philosophy* (Spring 2017 ed.). Stanford University.

Bryant, N. J., Govers, R., & James, D. E. (2002). Regulated transport of the glucose transporter GLUT4. *Nature Reviews Molecular Cell Biology*, 3(4), 267–277. https://doi.org/10.1038/nrm782

Burr, H. S. (1972). *Blueprint for Immortality: The Electric Patterns of Life*. Neville Spearman.

Chernet, B. T., & Levin, M. (2014). Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at long-range. *Oncotarget*, 5(10), 3287-3306. https://doi.org/10.18632/oncotarget.1935

Denton, R. M. (2009). Regulation of mitochondrial dehydrogenases by calcium ions. *Biochimica et Biophysica Acta (BBA)-Bioenergetics*, 1787(11), 1309-1316. https://doi.org/10.1016/j.bbabio.2009.01.005

Durant, F., Bischof, J., Fields, C., Morokuma, J., LaPalme, J., Hoi, A., & Levin, M. (2019). The role of early bioelectric signals in the regeneration of planarian anterior/posterior polarity. *Biophysical Journal*, 116(5), 948-961. https://doi.org/10.1016/j.bpj.2019.01.029

Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., ... & Greene, H. L. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. *New England Journal of Medicine*, 324(12), 781-788. https://doi.org/10.1056/NEJM199103213241201

Ellis, G. F. R. (2016). *How Can Physics Underlie the Mind? Top-Down Causation in the Human Context*. Springer.

Fang, X., Wang, K., Han, D., He, X., Wei, J., Zhao, L., ... & Li, Y. (2016). Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: A dose-response meta-analysis of prospective cohort studies. *BMC Medicine*, 14(1), 1-13. https://doi.org/10.1186/s12916-016-0742-z

Haldane, J. S. (1931). *The Philosophical Basis of Biology*. Hodder and Stoughton.

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine*, 359(15), 1577-1589. https://doi.org/10.1056/NEJMoa0806470

Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. *Nature*, 444(7121), 860-867. https://doi.org/10.1038/nature05485

Hubbard, S. R. (2013). The insulin receptor: Both a prototypical and atypical receptor tyrosine kinase. *Cold Spring Harbor Perspectives in Biology*, 5(3), a008946. https://doi.org/10.1101/cshperspect.a008946

Jahn, R., & Fasshauer, D. (2012). Molecular machines governing exocytosis of synaptic vesicles. *Nature*, 490(7419), 201-207. https://doi.org/10.1038/nature11320

Kaiser, M. I. (2015). *Reductive Explanation in the Biological Sciences*. Springer.

Kuhn, T. S. (1962). *The Structure of Scientific Revolutions*. University of Chicago Press.

Lerner, A., Jeremias, P., & Matthias, T. (2015). The world incidence and prevalence of autoimmune diseases is increasing. *International Journal of Celiac Disease*, 3(4), 151-155. https://pubs.sciepub.com/ijcd/3/4/8

Levin, M. (2021). Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. *Cell*, 184(8), 1971-1989. https://doi.org/10.1016/j.cell.2021.02.034

Mathews, J., & Levin, M. (2017). Gap junctional signaling in pattern regulation: Physiological network connectivity instructs growth and form. *Developmental Neurobiology*, 77(5), 643-673. https://doi.org/10.1002/dneu.22405

Morth, J. P., Pedersen, B. P., Toustrup-Jensen, M. S., Sørensen, T. L. M., Petersen, J., Andersen, J. P., ... & Nissen, P. (2007). Crystal structure of the sodium–potassium pump. *Nature*, 450(7172), 1043-1049. https://doi.org/10.1038/nature06419

Needham, J. (1936). *Order and Life*. Yale University Press.

Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*, 356(24), 2457-2471. https://doi.org/10.1056/NEJMoa072761

Noble, D. (2012). A theory of biological relativity: No privileged level of causation. *Interface Focus*, 2(1), 55-64. https://doi.org/10.1098/rsfs.2011.0067

Noble, D. (2017). *Dance to the Tune of Life: Biological Relativity*. Cambridge University Press.

Ozcan, L., de Souza, A. C., Harari, A. A., Bhatt, D. L., ... & Tabas, I. (2013). Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. *Cell Metabolism*, 18(6), 803–815. https://doi.org/10.1016/j.cmet.2013.10.011

Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of insulin action and insulin resistance. *Physiological Reviews*, 98(4), 2133-2223. https://doi.org/10.1152/physrev.00063.2017

Simon, H. A. (1962). The architecture of complexity. *Proceedings of the American Philosophical Society*, 106(6), 467-482.

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., ... & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice*, 183, 109119. https://doi.org/10.1016/j.diabres.2021.109119

Taylor, R. (2013). Type 2 diabetes: Etiology and reversibility. *Diabetes Care*, 36(4), 1047-1055. https://doi.org/10.2337/dc12-1805

Tseng, A. S., & Levin, M. (2013). Cracking the bioelectric code: Probing endogenous ionic controls of pattern formation. *Communicative & Integrative Biology*, 6(1), e22595. https://doi.org/10.4161/cib.22595

Whitty, C. J. M., & Watt, F. M. (2020). Map clusters of diseases to tackle multimorbidity. *Nature*, 579(7800), 494-496. https://doi.org/10.1038/d41586-020-00837-4